Telcon RF Pharmaceutical Completes 5 Billion Won Third-Party Allocation Capital Increase
Telcon RF Pharmaceutical has completed a third-party allocation paid-in capital increase worth 5 billion won, targeting Evercore Investment Holdings.
According to Telcon RF Pharmaceutical on July 28, the newly issued shares through the capital increase amount to 2,329,916 common shares, with each new share priced at 2,146 won. These newly issued shares will be subject to a one-year lock-up period starting from the listing date.
Telcon RF Pharmaceutical also participated in the third-party allocation paid-in capital increase of KPM Tech, aiming to more efficiently reorganize the group’s capital structure and cross-shareholding relationships among its affiliates.
During this round of capital restructuring, some intercompany loans among affiliates were settled through a debt-to-equity conversion, thereby alleviating the group’s financial burden. Each company has now established a foundation for pursuing mid-to-long-term growth strategies based on capital expansion and improved financial structures.
Telcon RF Pharmaceutical’s pharmaceutical division continues its stable growth trajectory, focusing on its gastrointestinal protective product lineup (Aljicell Solution, active ingredient sodium alginate), while also expanding investment in production and logistics infrastructure. Construction is currently underway for a palletizer to boost productivity and a high-rack warehouse with a capacity of 2,000 cells to increase efficiency in inbound and outbound processes for contract manufacturing partners’ products.
Hot Picks Today
Is the Stock Market Decline Just Beginning? "An Even Bigger Crisis Is Coming," Warns Rich Dad Author
- Seohak Ants Flock to SK hynix ADRs Despite Higher Taxes—Why?
- [Click eStock] Still Room to Rise... Data Center and Pre-sales Raise Expectations for This Construction Stock
- It Was a Sensation in Korea Too..."Can't Live Without It" - Japanese Elementary Students Also Obsessed With This
- "Prettier Than Idols?" "Tight Outfits Stir Debate"... Why the Virtual Female Weathercaster Is Causing a Stir
An official from Telcon RF Pharmaceutical said, “This paid-in capital increase is a strategic decision to enhance the efficiency of cross-shareholding within the group and to establish a stable governance structure. Building on this clarified governance, we will prioritize improving management efficiency and business competitiveness, and do our utmost to enhance corporate value and shareholder value.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
